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IntroductIon
Tissue regeneration is a well-orchestrated process that oc-
curs after injury caused by disease, trauma or, in some cases, 
drug intake. Complete regeneration leads to full restoration 
to health (restitutio ad integrum), whereas incomplete or de-
fective regeneration can lead to loss of tissue mass or replace-
ment with fibrotic scars, which are associated with impaired 
functional recovery. Understanding the molecular events un-
derlying the regeneration process and developing agents that 
aid regeneration is essential for patients with injured tissues in 
a variety of clinical settings. Because acute inflammation and 
tissue regeneration follow tissue damage, they are unavoidably 
entangled, and it is often stated that there can be no regenera-
tion without inflammation (Karin and Clevers, 2016).
High mobility group box 1 (HMGB1) protein is one 
of the endogenous molecules released on injury and is re-
sponsible for triggering inflammation (Scaffidi et al., 2002). 
HMGB1 is a highly conserved nuclear protein that binds to 
the minor groove of DNA and acts as a DNA chaperone 
that helps the binding of transcription factors to DNA and 
the formation of nucleosomes (Celona et al., 2011). HMGB1 
appears to be essential for life because Hmgb1 knockout mice 
die perinatally (Calogero et al., 1999). Beside its nuclear ac-
tivities, HMGB1 also functions as a signal of tissue damage 
or a damage-associated molecular pattern when released pas-
sively or actively in the extracellular medium (Scaffidi et al., 
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2002). Others and we previously demonstrated that sequen-
tial oxidation of cysteines modulates and eventually abrogates 
HMGB1 functions (Venereau et al., 2012, 2013; Yang et al., 
2012). Fully reduced HMGB1 (fr-HMGB1) associates with 
the chemokine CXCL12 and activates the CXCR4 receptor 
(Schiraldi et al., 2012), acting as a chemoattractant for cells, 
whereas HMGB1 containing a disulfide bond (ds-HMGB1) 
is a proinflammatory molecule that interacts with the TLR4 
adaptor myeloid differentiation factor-2 (MD-2; Yang et al., 
2015); further cysteine oxidation to sulfonates by reactive 
oxygen species abrogates both activities (Venereau et al., 
2012). To dissect the various activities of HMGB1, we created 
a mutant (3S) in which the cysteines are replaced with serines, 
which are resistant to oxidation. The 3S mutant behaves as the 
reduced form of HMGB1 (Venereau et al., 2012, 2013).
We show here that HMGB1, in different redox forms 
that act on distinct receptors, either promotes inflammation 
or orchestrates tissue regeneration. Pharmacological treatment 
with HMGB1, in particular the 3S variant, can accelerate re-
generation without exacerbating inflammation in muscle and 
liver, two paradigms for regenerative medicine and biology.
rESuLtS
Fully reduced HMGB1 and 3S promote muscle regeneration 
after acute muscle injury
Several studies have suggested a role of HMGB1 in muscle 
regeneration; in particular, heterozygous Hmgb1+/− mice, 
which express 50% less HMGB1 when compared with WT 
mice, have delayed muscle regeneration after acute injury 
(Dormoy-Raclet et al., 2013). We tested whether providing 
alternative redox forms of HMGB1 would accelerate muscle 
regeneration in WT mice. We injured tibialis anterior (TA) 
muscles with cardiotoxin (Ctx) and simultaneously injected 
recombinant fully reduced HMGB1 (fr-HMGB1) or disul-
fide HMGB1 (ds-HMGB1). Both promoted a significant 
increase in the expression of the satellite cell marker Pax7 
and the myogenic factors MyoD and Myogenin (Braun et 
al., 1989; Seale et al., 2000) compared with vehicle-injected 
mice (Fig. 1 A). However, HMGB1’s two redox forms can 
be interconverted in vivo, and their relative contribution 
cannot be evaluated. We therefore performed similar experi-
ments with 3S, which is resistant to oxidation and function-
ally similar to fr-HMGB1 (Venereau et al., 2012). Notably, 
3S treatment induced a significant increase of Pax7, MyoD, 
and Myogenin expression at early time points and a faster 
decrease at late time points (Fig. 1 B). These results indicated 
that ds-HMGB1 is likely not responsible for the induction of 
myogenic genes and suggested that 3S treatment might accel-
erate muscle regeneration. Indeed, the fraction of myofibers 
positive for staining with Evans blue dye (EBD), a reliable in 
vivo marker of damage, was significantly lower at day 5 in 
mice treated with 3S compared with control mice (Fig.  1, 
C–E). The EBD-negative fibers were centrally nucleated, and 
their cross-sectional area (CSA; a measure of regeneration) 
was significantly increased by ∼56% in 3S-treated mice com-
pared with controls (Fig. 1 F). At day 15, the myofiber CSA 
in 3S-treated mice was comparable to that of control mice 
but not larger, indicating the absence of any excessive cellu-
lar growth or hypertrophy (Fig. 1 F). Finally, we observed a 
highly significant increase at day 15 in the number of regen-
erated fibers (myofibers with nuclei at the periphery) in the 
3S-treated mice (80 ± 9%) compared with in mice treated 
with fr-HMGB1 (31 ± 6%) or vehicle (18 ± 1%; Fig. 1 G). 
In addition, the CD31+ endothelial area was increased in 
3S-treated mice (Fig. 1 H), indicating that angiogenesis was 
also improved. Regenerating muscles of 3S-injected mice 
exerted a tetanic force significantly greater than muscles of 
vehicle-injected mice (Fig. 1 I). Overall, these findings clearly 
demonstrate that one single treatment with 3S considerably 
accelerates muscle regeneration.
HMGB1 directly acts on muscle stem cells 
to support muscle repair
The number of Pax7+ cells (quiescent/activated satellite 
cells) was increased by ∼77% in 3S-treated mice at day 5 
after injury compared with vehicle-treated mice (Fig. 2 A), 
suggesting that the regenerative properties of HMGB1 were 
mediated by muscle stem cells. HMGB1 forms a heterocom-
plex with the chemokine CXCL12 to induce cell migration 
via CXCR4, in particular fibroblasts and leukocytes (Schi-
raldi et al., 2012). Ex vivo migration experiments showed that 
both fr-HMGB1 and 3S were chemoattractant for Pax7+ cells 
and as effective as the conventional positive control human 
growth factor (Bischoff, 1997; Fig. 2 B).
On injury, satellite cells get activated, proliferate, differ-
entiate, and fuse to form new myofibers. To further investigate 
the effects of HMGB1 on such processes, we isolated single 
myofibers and analyzed the expression of specific markers: 
Pax7 (quiescent/activated satellite cells), MyoD (activated/
proliferating myoblasts), and Myogenin (differentiating myo-
blasts). After 72 h of culture in the presence of fr-HMGB1 or 
3S, the total number of myoblasts was significantly higher rela-
tive to the control, in particular the number of MyoD-positive 
cells, suggesting that treatment with HMGB1/3S promoted 
activation and proliferation of myoblasts (Fig. 2, C and D). In-
deed, the total number of myoblasts was already significantly 
increased at 16 h, in particular the number of activated myo-
blasts (Pax7−MyoD+ cells), whereas the number of quiescent 
satellite cells (Pax7+MyoD− cells) was significantly decreased 
(Fig. 2 E). Both fr-HMGB1 and 3S induced the formation 
of larger myotubes from primary myoblasts (Fig. 2, F and G). 
Overall, these results identify HMGB1 as an activator of satel-
lite cell myogenic output; 3S is even more effective.
fr-HMGB1 and 3S establish a 
tissue-healing microenvironment
In the extracellular environment, HMGB1 is one of the main 
mediators in both acute and chronic inflammation. To in-
vestigate whether treatment with fr-HMGB1 or 3S might 
modulate the inflammatory state of the regenerating muscles, 
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Figure 1. Intramuscular injection of fr-HMGB1 or 3S accelerates muscle regeneration. (A) Muscle acute injury was induced by injection of Ctx in 
triceps muscles. Vehicle (PBS) or HMGB1 (fr-HMGB1 or ds-HMGB1) was injected at the same time as Ctx. Quantitative PCR of Pax7, MyoD, and Myogenin 
(Myog) mRNA in triceps was performed at day 5 after injury (fold increase vs. vehicle). The significance of the difference in gene expression between mice 
treated with HMGB1 (fr-HMGB1 or ds-HMGB1) and vehicle-treated mice was assessed with Mann-Whitney tests. *, P < 0.05; **, P < 0.01. n = 9 mice per 
group, three independent experiments. (B–I) Ctx was injected together with vehicle (PBS) or WT fr-HMGB1 (HMGB1) or 3S in TA and/or triceps muscles. 
Muscle regeneration was assessed at days 2, 5, 10, 15, and 20 after injury. (B) Quantitative PCR of Pax7, MyoD, and Myog mRNA in triceps at days 5, 10, 
15, and 20 after injury (fold increase vs. uninjured muscles). n ≥ 5 mice per group, at least two independent experiments. (c) TA muscles, stained with 
EBD, at days 5 and 15 after injury. (d) EBD, laminin, and DAPI staining of TA muscle sections at days 2, 5, and 15 after injury. Bars, 50 µm. (E) Percentage 
of EBD-positive myofibers in regenerating TA muscles at day 5 after injury. n = 4 mice per group, two independent experiments. (F) CSA of fibers in TA 
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we examined the infiltration of leukocytes. We previously 
showed that endogenous fr-HMGB1 forms a heterocomplex 
with the chemokine CXCL12 that recruits leukocytes into 
injured muscles (Schiraldi et al., 2012). Only a slight increase 
of CD45+ cells was observed at day 1 after injury in muscles 
injected with fr-HMGB1 or 3S, suggesting that endogenous 
HMGB1 is already sufficient to promote optimal leukocyte 
recruitment (Fig. 3 A).
Recent work showed that HMGB1 modulates the po-
larization of macrophages (Schaper et al., 2016; Son et al., 
2016). The switch from a proinflammatory to a tissue-healing 
phenotype in macrophages is an essential step in muscle regen-
eration to limit the inflammatory response and favor myogen-
esis (Arnold et al., 2007; Cohen and Mosser, 2013; Saclier et 
al., 2013; Wang et al., 2014). Thus, we analyzed the expression 
of specific macrophage surface markers at day 5 after injury: 
CD68 for total macrophages, CD86 for proinflammatory, and 
CD163 for tissue-healing macrophages (Saclier et al., 2013). 
Treatment with fr-HMGB1 or 3S increased, respectively, by 
∼80% and 97% the number of CD163+ macrophages in the 
muscle relative to controls (Fig. 3, B and C). Expression of 
insulin-like growth factor-1 (IGF-1), a potent enhancer of 
tissue regeneration that promotes macrophage polarization 
toward the tissue-healing phenotype (Lefaucheur and Sébille, 
1995; Lu et al., 2011; Tonkin et al., 2015), was also signifi-
cantly increased in 3S-treated mice at day 5 after injury com-
pared with vehicle controls (Fig.  3 D). Similarly, treatment 
of bone marrow–derived macrophages with fr-HMGB1 or 
3S, in proinflammatory polarizing conditions, increased the 
expression of markers of the tissue-healing phenotype, such as 
CD163 and TGF-β (Fig. 3, E and F). Collectively, these data 
reveal that fr-HMGB1 and 3S act on myoblasts and macro-
phages to promote muscle regeneration rather than inflam-
mation. Conversely, the marked delay of muscle regeneration 
in Hmgb1+/− mice after acute injury was associated with a 
defect in angiogenesis and in mobilization of satellite cells and 
leukocytes (Fig. 4); in particular both CD163+ macrophages 
and Pax7+ cells were sparser in injured muscles of Hmgb1+/− 
mice compared with WT (Fig. 4, F–H).
Alternative redox forms of HMGB1 contribute to muscle 
repair or inflammation by binding to different receptors
Our results indicate that the regenerative properties of HMGB1 
are dictated by its redox state, and we next asked which HMGB1 
receptor or receptors are involved in muscle regeneration. 
ds-HMGB1 binds TLR4 via the adaptor protein MD-2, and 
cysteine 106 is essential (Yang et al., 2010, 2015). Surface plas-
mon resonance (SPR) experiments showed that 3S, in which 
cysteine 106 is mutated to serine, binds to MD-2 with a very 
low affinity compared with ds-HMGB1 (Fig. 5 A), in agreement 
with its inability to induce cytokine and chemokine expression 
in macrophages (Venereau et al., 2012). The receptor for ad-
vanced glycation end products (RAGE) also preferentially bound 
to ds-HMGB1 (Fig. 5 B), and 3S bound inefficiently. These re-
sults suggested that the regenerative properties of fr-HMGB1 
and 3S were not mediated by TLR4/MD-2 or RAGE, con-
trary to the inflammatory activities of ds-HMGB1. Indeed, 3S 
promoted muscle regeneration when injected in the muscles of 
Ctx-injured WT, Tlr4−/−, and Rage−/− mice, with no significant 
differences between the different genotypes (Fig. 5 C).
HMGB1 forms a heterocomplex with the chemokine 
CXCL12 to induce cell migration via CXCR4 (Schiraldi et 
al., 2012). By analogy, we explored the involvement of the 
CXCL12/CXCR4 axis in HMGB1-mediated regeneration. 
To analyze the binding of 3S to CXCR4, we performed SPR 
experiments with immobilized lentiviral particles expressing 
CXCR4 on their surface (Vega et al., 2011). As reported pre-
viously (Schiraldi et al., 2012), fr-HMGB1 failed to bind to 
CXCR4 in the absence of CXCL12 (Fig. 5 D). Surprisingly, 
we found that 3S directly bound to CXCR4, with an affinity 
10-fold higher than that of CXCL12 itself (KD of 6.44 vs. 76.9 
nM; Fig. 5, D and E; and Table 1). We also found that BoxA, a 
truncated form of HMGB1 used as an antagonist of HMGB1, 
was able to bind to CXCR4 with high affinity (KD, 6.66 nM) 
in the absence of CXCL12 (Fig. 5, D and E; and Table 1). Ac-
cordingly, 3S-induced migration is mediated by CXCR4, be-
cause Cxcr4−/− cells did not migrate toward 3S (Fig. 5 F) and 
anti-CXCL12 antibodies inhibited the migration of myoblasts 
toward fr-HMGB1 but had no effect on migration toward 3S 
(Fig. 5 G). BoxA inhibited myoblast migration in response to 
3S or CXCL12, demonstrating that BoxA is a CXCR4 in-
hibitor (Fig. 5 H). Consistently, BoxA abrogated the beneficial 
effects of 3S (Fig. 6, A–C), in particular the expansion of Pax7+ 
cells and CD163+ cells (Fig. 6, D and E). Interestingly, BoxA 
also interfered with the unaided muscle regeneration process 
(Fig. 6, A–E) and so did treatment with AMD3100/Plerixa-
for, the most widely used CXCR4 antagonist (Fig. 6, F–H). 
AMD3100 binds to CXCR4 with an affinity similar to that of 
CXCL12 (Rosenkilde et al., 2004), whereas 3S has a 10-fold 
higher affinity (Table  1). Accordingly, 3S was able to restore 
muscle regeneration in AMD3100-treated mice (Fig. 6, F–H). 
Overall, our findings demonstrate that CXCR4 plays a central 
role in muscle regeneration and that 3S can bypass the need for 
CXCL12 by directly interacting with CXCR4.
muscles at days 5 and 15 after injury. n ≥ 5 mice per group, at least two independent experiments. (G) Quantification of myofibers with nuclei at the pe-
riphery (PNF) in TA muscles at day 15 after injury. n = 5 mice per group, two independent experiments. (H) CD31 and DAPI staining on TA muscle sections 
at day 15 after injury and relative quantification of CD31+ area. n = 3 mice per group of three independent experiments. Bars, 50 µm. (I) Tetanic force of TA 
muscles: uninjured (No Ctx), cardiotoxin-injured (Ctx), Ctx-injured treated with 3S (Ctx + 3S), at day 10 after injury. n = 5 mice per group, two independent 
experiments. Differences between groups in B and E–I were assessed with one-way ANO VA plus Dunnett’s post-test; data are means ± SEM. *, P < 0.05; 
**, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
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Figure 2. fr-HMGB1/3S promotes skeletal muscle regeneration by acting on satellite cells. (A) TA muscle acute injury was induced by injection of 
Ctx; vehicle (PBS) or WT fr-HMGB1 (HMGB1) or 3S was injected together with Ctx. Pax7+ cells were quantified in regenerating TA muscles at days 5 and 15 
after injury. n = 3 mice per group, two independent experiments. (B) Ex vivo migration of primary mouse Pax7+ cells toward 40 nM HMGB1 (fully reduced) or 
3S. Hepatocyte growth factor (HGF) was used as the positive control. n = 3 independent experiments. (c–E) Single myofibers isolated from mouse muscles 
were cultured in proliferation medium for 72 (C and D) or 16 h (E) with or without 40 nM fr-HMGB1 or 3S. Relative numbers of MyoD+ and/or Myogenin+ 
cells at 72 h (D) and of Pax7+ and/or MyoD+ cells at 16 h (E) on single fibers. n = 3 mice, 10 fibers/mouse, three independent experiments. Bars, 50 µm. 
(F and G) Representative images of mouse primary myoblasts cultured for 48 h in differentiating medium, with or without 40 nM fr-HMGB1 or 3S, and 
stained with DAPI and anti–myosin heavy chain (MHC) antibody (F), and distribution of myofiber size (G). Bar, 100 µm. The differences between control and 
treatments are statistically significant (P < 0.0001, χ2 test). Data are representative of two independent experiments with biological triplicates. Data are 
means ± SEM. Statistical significance was assessed with one-way ANO VA plus Dunnett’s post-test in A, B, D, and E. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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3S promotes liver regeneration without 
exacerbating inflammation
We then asked whether 3S promotes regeneration in other 
tissues. We examined liver regeneration, which is one of the 
most studied models of tissue regeneration. Previous studies 
have demonstrated that endogenous HMGB1 is a mediator 
of drug-induced hepatoxicity by promoting inflammation via 
its interaction with TLR4/MD-2 (Antoine et al., 2012; Yang 
et al., 2015). Hence, the drug-induced liver injury (DILI) 
model represents an ideal system to evaluate the regenera-
Figure 3. fr-HMGB1/3S modulates macrophage polarization toward a tissue-healing phenotype. (A–d) TA muscles were injected with 
Ctx alone or Ctx plus WT fr-HMGB1 (HMGB1) or 3S. (A) Quantification of CD45+ cells isolated from injured muscles at days 1 (n = 5 mice per group 
of three independent experiments) and 2 (n = 3 mice per group of three independent experiments) after injury. (B and C) Representative immuno-
fluorescence staining for CD68, CD86, and CD163 on sections of TA muscles at day 5 after injury (B) and quantification of CD68+ (n = 3 mice per 
group), CD68+CD86+, and CD68+CD163+ cells (n = 5 mice per group) in sections of TA muscles (C), two independent experiments. Bars, 50 µm. 
(D) Quantitative PCR of IGF-1 mRNA in triceps at day 5 after injury. n = 9 mice per group of three independent experiments. (E and F) Mouse bone mar-
row–derived macrophages were cultured for 7 d in DMEM conditioned by L929 cells (enriched in CSF-1) and polarized for 3 d toward a proinflammatory 
phenotype by stimulation with IFNγ (50 ng/ml) with or without 40 nM fr-HMGB1 or 3S. Representative images of macrophages (E) and quantification of 
cells positive for iNOS, TNFα, TGFβ, and CD163 expression, analyzed by immunofluorescence staining (F; fold increase vs. control; at least three independent 
experiments). Bars, 50 µm. Data are means ± SEM. Statistical significance was assessed with one-way ANO VA plus Dunnett’s post-test in A, C, D, and F. 
*, P < 0.05; **, P < 0.01; ***, P < 0.001.
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tive and noninflammatory properties of 3S. We first analyzed 
HMGB1 expression in healthy and acetaminophen (APAP)- 
intoxicated livers (Fig.  7  A). Notably, hepatocytes abutting 
the APAP-induced injury had HMGB1-negative nuclei, in-
dicating that they secreted HMGB1. We administered 3S sys-
temically 2 h after APAP injection. Vehicle- and 3S-treated 
mice had similar levels of serum alanine aminotransferase 
(sALT) and serum aspartate aminotransferase (sAST; Fig. 7 B). 
Thus, 3S does not modulate APAP-induced liver injury. Ac-
cordingly, flow cytometry quantification of intrahepatic sub-
populations of leukocytes showed no significant difference 
between vehicle- or 3S-treated mice (Fig. 7 C).
In contrast to muscle, liver regeneration does not rely 
on stem cells but on differentiated hepatocytes, which pro-
liferate in a highly regulated manner after loss of liver mass. 
Interestingly, hepatocyte proliferation occurred significantly 
earlier in 3S-treated mice: the number of Ki67-positive he-
patocytes was higher at days 2 and 3 after APAP injection 
Figure 4. High expression of HMGB1 is re-
quired for optimal skeletal muscle regen-
eration. Muscle acute injury was induced by 
injection of Ctx in TA and/or triceps muscles 
of WT or Hmgb1+/− mice, and regeneration 
was assessed at day 5 after injury. (A) H&E 
and immunofluorescence staining (DAPI and 
CD31) of TA muscle sections from WT and 
Hmgb1+/− mice at day 5 after injury. Bars, 50 
µm. (B) Quantification of CD31-positive cells/
mm2 in TA muscles of WT and Hmgb1+/− mice 
at day 5 after injury. n = 4 mice per group of 
three independent experiments. (c) Quantita-
tive PCR analysis of mRNA levels of angiopoi-
etin-1 (Ang-1) in triceps at day 5 after injury. 
n = 6 mice per group of two independent 
experiments. (d) Representative immuno-
staining (DAPI and CD45, top; DAPI and CD68, 
bottom) of TA muscle sections from WT and 
Hmgb1+/− mice at day 5 after injury. Bars, 50 
µm. (E) Quantification of CD45-positive cells 
isolated with immunobeads from injured 
muscles. n = 6 mice per group of two inde-
pendent experiments. (F) Quantification of 
CD68-positive cells (n = 4 mice) and CD68/
CD163-positive macrophages (n = 3 mice) in TA 
muscle sections from WT and Hmgb1+/− mice 
at day 5 after injury, two independent exper-
iments. (G) Representative immunofluores-
cence staining for DAPI, laminin, and Pax7 in TA 
muscles from WT and Hmgb1+/− mice at day 5 
after injury (Pax7-positive cells indicated with 
white arrowheads). Bars, 50 µm. (H) Quantifi-
cation of Pax7-positive cells in TA muscles of 
WT and Hmgb1+/− mice at day 5 after injury. 
n = 3 mice per group of two independent ex-
periments. In all panels, data are means ± SEM, 
and statistical significance was assessed with 
Student’s t test. *, P < 0.05; **, P < 0.01.
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compared with control mice and declined already at day 5 
(Fig. 7, D and E). To investigate the role of CXCR4 in the 
DILI model, we administered 3S, AMD3100, or a combina-
tion of both, 2 h after APAP injection. All groups of mice had 
similar APAP-induced liver injury, indicating that the differ-
ent treatments did not cause further liver damage (Fig. 7 F). 
At day 2 after APAP injection, when liver regeneration was 
starting, AMD3100-treated mice had a lower number of 
BrdU-positive hepatocytes compared with control mice, in-
dicating that CXCR4 blockade inhibits hepatocyte prolifer-
ation (Fig. 7, G and H). Overall, our findings indicate that 3S 
is noninflammatory in a DILI model in contrast to endog-
enous HMGB1 and conversely promotes liver regeneration 
through the CXCR4 receptor.
dIScuSSIon
In this study we have shown that HMGB1 coordinates tis-
sue repair and inflammation by switching among alternative 
redox forms. Specifically, fr-HMGB1 promotes muscle and 
liver repair through several cell-specific responses mediated 
Figure 5. 3S and BoxA directly bind to cXcr4. (A and B) SPR sensorgrams representing the binding of HMGB1 isoforms to immobilized MD-2 (A) 
or sRAGE (B). ds-HMGB1 and 3S bind to MD-2 with an apparent KD of 0.35 µM and 2 µM, respectively (A). Binding to sRAGE: apparent KD of 1 µM for 
ds-HMGB1 and 3.5 µM for fr-HMGB1 and 3S (B). Data are representative of three independent experiments. (c) TA muscles of WT, Tlr4−/− and Rage−/− mice 
were injected with Ctx and vehicle (PBS) or 3S, and the CSA of centronucleated fibers was measured at day 5 after injury. n = 3 mice per group, two inde-
pendent experiments. Data are means ± SEM. Student t tests within each genotype: *, P < 0.05; **, P < 0.01. (d) Sensorgrams representing the binding of 40 
nM fr-HMGB1 or 3S, 50 nM CXCL12, and 40 nM BoxA to immobilized lentiviral particles with membrane-bound CXCR4. (E) Sensorgrams representing the 
binding of different concentrations of 3S (left) or BoxA (right) to immobilized lentiviral particles with membrane-bound CXCR4. Curves derived from these 
assays were analyzed by fitting to a simple one-site interaction model with BIA Evaluation 4.1 software (GE Healthcare). Data are representative of three 
independent experiments. (F) Migration of WT (Cxcr4+/+) or Cxcr4−/− MEFs toward 0.4 nM fr-HMGB1 or 3S. Data are representative of three independent 
experiments and are means ± SEM. Statistical significance between genotypes was calculated with Student’s t test. ***, P < 0.001; ****, P < 0.0001. (G and H) 
Migration of myoblasts toward 40 nM fr-HMGB1 and 3S with or without 10 nM anti-CXCL12 antibody (G) or toward 40 nM 3S and 30 nM CXCL12 with or 
without 250 nM BoxA (H). Data are means ± SEM of triplicates, two independent experiments. Differences between treatments were assessed with one-way 
ANO VA plus Tukey’s post-test. *, P < 0.05; **, P < 0.01, ***, P < 0.001.
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by CXCR4, whereas ds-HMGB1, which triggers and sustains 
inflammation via the TLR4/MD-2 and RAGE receptors, is 
not involved in regeneration. HMGB1 needs to form a com-
plex with CXCL12 to interact with CXCR4 (Schiraldi et 
al., 2012) and appears to be a limiting factor in physiolog-
ical conditions, because the reduction of HMGB1 content 
in Hmgb1+/− mice delays muscle repair (Dormoy-Raclet et 
al., 2013), whereas the injection of exogenous fr-HMGB1 
sizably accelerates it. The 3S variant is a nonoxidizable form 
of HMGB1, which cannot be converted to ds-HMGB1 
or be inactivated by sulfonylation. Notably, 3S binds ineffi-
ciently to TLR4/MD-2 and RAGE, the receptors mediat-
ing the inflammatory properties of HMGB1, but it directly 
binds to CXCR4 with high affinity, bypassing the require-
ment for CXCL12. Accordingly, 3S is more effective than 
the WT protein in promoting regeneration and does not 
exacerbate inflammation.
HMGB1 is a ubiquitous protein that is released by all 
cell types upon injury, and consequently it might contribute 
to regeneration in multiple tissues. Indeed, HMGB1 appears 
to exert beneficial effects under several pathological condi-
tions by recruiting different types of stem or progenitor cells 
and promoting their proliferation (Palumbo et al., 2004; Li-
mana et al., 2005; Chavakis et al., 2007; Deneault et al., 2009; 
Tamai et al., 2011). Similarly, the CXCL12/CXCR4 axis has 
been reported to activate the body’s own tissue repair path-
ways, and different strategies aimed at increasing CXCL12 
availability have been tried to facilitate tissue repair (Lau and 
Wang, 2011). We now show that the critical ligand (or coli-
gand) of CXCR4 in muscle and liver regeneration is HMGB1. 
Muscle and liver have very different tissue architectures and 
rely on different cellular mechanisms for regeneration: mus-
cle relies on local stem cells, the satellite cells, and liver relies 
on the proliferation capacities of hepatocytes. Based on these 
extreme differences, and the common regeneration responses 
to 3S, we suggest that the HMGB1/CXCR4 axis may be 
involved in the repair and regeneration of most tissues.
Since the discovery of its extracellular release, most 
attention has been paid to the contribution of HMGB1 to 
inflammation. Our data demonstrate that fr-HMGB1 and 
3S are devoid of proinflammatory activities, indicating that 
the HMGB1 redox form responsible for inflammation is 
ds-HMGB1, acting via RAGE and TLR4 signaling. Accord-
ingly, ds-HMGB1 has been reported to be the isoform re-
sponsible for DILI, neuroinflammation, epilepsy, thrombosis, 
and pain (Agalave et al., 2014; Balosso et al., 2014; Yang et al., 
2015; Stark et al., 2016; Lian et al., 2017). Conversely, mice 
deficient in HMGB1 in specific cell types—intestinal epithe-
lial cells, pancreatic cells, hepatocytes, or monocytes—display 
worsened phenotypes of inflammatory bowel disease, pan-
creatitis, liver damage after ischemia/reperfusion, and sepsis, 
respectively (Yanai et al., 2013; Huang et al., 2014; Kang et 
al., 2014; Zhu et al., 2015). Although the beneficial role of 
HMGB1 in these models has been mostly attributed to its 
intracellular functions, it is equally possible that the worsened 
outcome after insult is due to a defective repair of the dam-
aged tissue. Therapeutic strategies aiming at the prevention 
of HMGB1 oxidation, rather than HMGB1 neutralization, 
might be useful in diverse clinical settings to fine-tune the 
pharmacological control of inflammation and to support 
tissue regeneration. Accordingly, the current therapy for 
APAP intoxication is the administration of the antioxidant 
N-acetylcysteine (NAC). Based on our results, the efficacy of 
NAC could be explained, at least in part, by the shift in balance 
between deleterious ds-HMGB1 and beneficial fr-HMGB1.
Several strategies have been developed so far to coun-
teract the extracellular activities of HMGB1. A truncated 
form of HMGB1, BoxA, has been extensively used in vivo to 
inhibit HMGB1, and its protective effects have been demon-
strated in multiple mouse models of pathological conditions 
(Venereau et al., 2016). However, its mechanism of action has 
not been fully elucidated yet. Notably, we show that BoxA 
interacts directly with CXCR4 and suppresses the activity of 
both 3S and CXCL12, indicating that BoxA is an antagonist of 
CXCR4. Hence, some effects of BoxA might be attributed to 
the inhibition of the CXCL12/CXCR4 axis, in particular in 
the context of cell recruitment and cancer (Guo et al., 2016).
More generally, this study provides an example in which 
the organism uses the same molecule in alternative redox 
forms to orchestrate sequential physiological processes after 
tissue injury—signaling damage, triggering inflammation, and 
eventually promoting regeneration. Of most direct utility, we 
identified 3S as a promising drug candidate to promote tissue 
repair without exacerbating inflammation. In agreement with 
our findings, 3S has been recently demonstrated to exert no 
deleterious effects in neuroinflammation, excitotoxicity, and 
thrombosis (Balosso et al., 2014; Stark et al., 2016; Lian et al., 
2017), contrary to WT HMGB1. The ability to safely accel-
erate regeneration with a single administration of 3S (locally 
in the muscle or systemically in the liver) opens up promising 
therapeutic opportunities for regenerative medicine.
MAtErIALS And MEtHodS
Mice and injury models
8-wk-old C57BL/6 mice were purchased from Charles River 
Laboratories. Hmgb1+/−, Tlr4−/−, Rage−/−, and Pax7-ZsGreen 
mice (C57BL/6), were bred in the animal facility at San Raffa-
ele Scientific Institute. All mice were housed under standard or 
Table 1. Kinetic constants of cXcL12, 3S, and BoxA binding to 
cXcr4
Ligand Ka Kd KD
1/Ms 1/s nM
CXCL12 1.5 × 105 5.83 × 10−2 76.9
3S 6.81 × 105 1.04 × 10−3 6.4
BoxA 5.75 × 106 2.3 × 10−2 6.7
Curves derived from binding of CXCL12, 3S, and BoxA to immobilized lentiviral particles 
with membrane-bound CXCR4 were used to generate kinetic constants (Ka, Kd, KD) by using 
a simple one-site interaction model with BIA Evaluation 4.1 software (GE Healthcare). Data 
are representative of three independent experiments.
 o
n
 February 28, 2018
jem.rupress.org
D
ow
nloaded from
 
HMGB1 orchestrates tissue regeneration via CXCR4 | Tirone et al.312
specific pathogen–free conditions and allowed access to food 
and water ad libitum. All experimental protocols were approved 
by the San Raffaele Institutional Animal Care and Use Com-
mittee (IAC UC 590 and 663) in accordance with Italian law. 
All efforts were made to minimize suffering. Male and female 
mice were used and always sex-matched in each experiment.
In the acute muscle injury model, animals were anaes-
thetized by i.p. injection of Avertin (T48402, 2,2,2-Tribro-
moethanol 97%; Sigma-Aldrich), and sterile injury was 
induced by injection of 50  µl 15-µM Ctx (C9759 Sigma- 
Aldrich) in TA and triceps muscles. Treatment with vehicle 
or HMGB1 (5 nmol WT fr-HMGB1 or 3S; HMGBiotech) 
Figure 6. HMGB1 supports muscle regen-
eration via cXcr4. (A–E) Comparison of 
C57BL/6 mice treated with Ctx plus vehicle 
versus Ctx plus BoxA and Ctx plus 5 mg/kg 3S 
with or without 10 mg/kg BoxA. (A) Laminin 
and DAPI staining of TA muscle sections at day 
5 after injury. Bar, 50 µm. Number (B) and CSA 
of centronucleated fibers (CNFs; C) in TA mus-
cles at day 5 after injury. n = 4 mice per group, 
two independent experiments. (D) Quantifica-
tion of Pax7+ cells in regenerating TA muscles 
at day 5 after injury. n = 3 mice per group, two 
independent experiments. (E) Quantification of 
CD68+CD163+ cells in sections of TA muscles 
at day 5 after injury. n = 4 mice per group, two 
independent experiments. (F–H) Comparison 
of muscles from mice receiving one single in-
tramuscular injection of Ctx plus vehicle (PBS) 
versus Ctx plus 5 mg/kg AMD3100 with or 
without 5 mg/kg 3S. (F) Representative images 
of H&E and immunofluorescence staining for 
DAPI and laminin or CD68/CD163. Bars, 50 
µm. (G) Number of CNFs in TA muscles at day 
5 after injury. n = 3 mice per group, two in-
dependent experiments. (H) Quantification of 
CD68+CD163+ cells on sections of TA muscles 
at day 5 after injury. n = 3 mice per group, 
two independent experiments. Differences 
between groups were assessed with one-way 
ANO VA plus Tukey’s post-test. *, P < 0.05; 
**, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
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was administered together with Ctx. Mice were sacrificed 
2, 5, 15, or 20 d after Ctx injection, and muscles were col-
lected and either sectioned for histological analysis or sub-
jected to RNA extraction.
For the DILI model, 8-wk-old C57BL/6 males were 
fasted 16 h before i.p. injection of 300 mg/kg (body weight) 
APAP (Sigma-Aldrich) dissolved in sterile warm saline. 2 h 
after APAP intoxication, mice received vehicle (NaCl) or 3S 
Figure 7. 3S accelerates liver regeneration 
via cXcr4. DILI was induced by i.p. injection 
of 300 mg/kg (body weight) APAP. 2  h later, 
mice received one single i.p. injection of vehi-
cle (NaCl), 500 µg/mouse 3S, or 200 µg/mouse 
AMD3100 with or without 500 µg/mouse 3S. 
Serum collection and necroscopy were per-
formed at different time points, and hepatic 
regeneration was assessed by i.p. injection of 
1 mg/mouse BrdU 16 h before liver collection. 
(A) Representative images of H&E staining 
and HMGB1 immunostaining of liver in con-
trol mice on day 1 after DILI. HMGB1 negative 
nuclei (white arrowheads) are visible at higher 
magnification of the areas identified by rect-
angles in APAP-treated mice. Bars, 50 µm. (B) 
sALT and sAST in serum after APAP injection 
in mice treated with vehicle or 3S. n = 6 mice 
per group, two independent experiments. (c) 
Quantification of intrahepatic leukocytes (IHL) 
at days 1, 2, 3, 5, and 7 after APAP injection 
in control mice and after DILI in mice treated 
with vehicle or 3S. n = 4 mice per group, two 
independent experiments. Data are means ± 
SEM, and differences between groups were as-
sessed with two-way ANO VA plus Bonferroni 
post-tests. The interaction between treatment 
and time is not significant. (d and E) Rep-
resentative images of Ki-67 immunostaining 
(D) and quantification of Ki-67–positive he-
patocytes (E) in livers from mice treated with 
vehicle or 3S at days 1, 2, 3, 5, and 7 after 
APAP injection. Bars, 50 µm. n = 4 mice per 
group, two independent experiments. Data 
are means ± SEM, and differences between 
groups were assessed with two-way ANO VA 
plus Bonferroni post-tests. The interaction be-
tween treatment and time is significant (P = 
0.0003). (F) sALT and sAST after APAP injection 
in mice treated with vehicle, 3S, or AMD3100 
with or without 3S. n = 4 mice per group, two 
independent experiments. Differences be-
tween groups in B and F were assessed with 
one-way ANO VA plus Dunnett’s post-test. (G 
and H) Representative images of BrdU im-
munostaining (G; BrdU-positive hepatocytes 
indicated with white arrowheads) and quan-
tification of BrdU-positive hepatocytes (H) in 
livers from mice treated with vehicle, 3S, or 
AMD3100 with or without 3S at day 2 after 
APAP injection. Bars, 50 µm. n = 4 mice per 
group. Data are means ± SEM, and differences 
between groups were assessed with one-way 
ANO VA plus Bonferroni post-tests. *, P < 0.05; 
**, P < 0.01; ***, P < 0.001.
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(500 µg/mouse), AMD3100 (200 µg/mouse; Sigma-Aldrich), 
or 3S and AMD3100 by i.p. injection. Transaminases (sALT 
and sAST) were quantified in serums at days 1, 2, 3, 5, and 7 
after APAP administration with an International Federation 
of Clinical Chemistry and Laboratory Medicine–optimized 
kinetic UV method in an ILab Aries chemical analyzer (In-
strumentation Laboratory), and they are expressed as U/liter. 
To assess hepatocyte proliferation, 16 h before sacrifice mice 
received 1 mg BrdU (Sigma-Aldrich) by i.p. injection.
Morphometry
Morphometric analyses were performed on sections collected 
from similar regions of each TA muscle. CSA and central 
nucleation analyses were performed on 500–750 fibers/TA 
muscle after laminin and DAPI immunostaining by using 
ImageJ software (http ://rsbweb .nih .gov /ij /).
Histology and immunofluorescence
Muscles were collected and embedded in OCT (Bio-Optica) 
or directly frozen in liquid nitrogen–cooled isopentane. Serial 
muscle sections, 8-µm thick, were stained with hematoxylin 
and eosin (H&E; Sigma-Aldrich) according to standard pro-
cedures. Immunofluorescence on frozen sections of muscles 
was performed as previously described (Brunelli et al., 2007) 
by using the following primary antibodies: chicken anti-lami-
nin (1:500; Sigma-Aldrich), rat anti-CD68 (1:100; AbD Sero-
tec, Bio Rad), rat anti-CD86 (1:100; BD-PharMingen), rabbit 
anti-CD163 (1:200; Santa Cruz Biotech), rat anti-CD31 (1:2, 
clone MEC13.3; gift from E. Dejana, Uppsala University, Up-
psala, Sweden). Appropriate Alexa Fluor (Alexa 488 or Alexa 
546)–conjugated antibodies (1:500; Invitrogen) were used as 
second-step reagent. Nuclei were counterstained with DAPI 
(1:1,000; Sigma Aldrich), and coverslips were mounted with 
Fluorescence Mounting Medium (Dako).
For Pax7 staining, 8-µm serial muscle sections were per-
meabilized with 0.2% Triton, 1% BSA in PBS for 30 min 
at room temperature and then blocked in 10% serum, 1% 
BSA solution in PBS for 30 min before incubation with the 
primary antibody (Pax7; Developmental Studies Hybridoma 
Bank), after an antigen retrieval step in sodium citrate 10 mM, 
pH 6.0, for 10 min between fixation and blocking steps (2 h).
Livers were collected, fixed in zinc-formalin, and then 
embedded in paraffin and stained with H&E, anti–Ki-67 
(1:100, clone SP6; Neomarkers) and anti-HMGB1 (1:200; 
BD PharMingen) and anti-BrdU (1:100, Abcam) antibodies.
Image acquisition and analyses
Fluorescent and phase contrast images were taken by using 
Nikon Eclipse E600 or Zeiss Imager M2 microscopes. Image 
acquisition was done by using the Nikon digital camera 
DXM1200 or AxioCam MRc5 camera and the acquisi-
tion software Nikon ACT-1 (Plan Fluor lenses: X4/0.13, 
X10/0.33, X20/0.50, X40/0.75) or AxioVision. Images 
showing double fluorescence were first acquired separately 
by using appropriate filters, and then the different layers were 
merged by using Adobe Photoshop CS6. Histological quan-
tifications were done by counting at least 20 fields (20× and/
or 40×) for each data point.
For the quantification of CD31-positive staining, the 
red signal from CD31 immunostaining was filtered by using 
the same parameters for all samples, and regions on the tis-
sue sections were marked to outline areas to be quantified. 
A morphological image processing operation, flood-fill, was 
used to identify the pixels within the image that belonged to 
the regions of interest. CD31-stained pixels were identified 
by thresholding red-to-blue channel intensity. An empiri-
cally determined low threshold of 1.1 was used to segment 
out CD31-positive regions.
All images of liver immunohistochemical staining were 
acquired by using the Aperio Scanscope CS2 system (Leica 
Biosystems). Quantifications of Ki-67– and BrdU-positive he-
patocytes were performed by automated image analysis soft-
ware through dedicated macros of the ImageScope program 
(Leica Biosystems) on liver sections of an area between 5 and 
30.4 mm2, as previously described (Catarinella et al., 2016).
Muscle force
TA muscles were dissected from mouse legs under a stereomi-
croscope (×10 to ×60) and transferred to the myograph to be 
mounted between the hooks of a force transducer (AME 801; 
Aksjeselkapet Mikkroelektronik). Preparations were placed 
in an organ bath filled with Krebs solution (120 mM NaCl, 
2.4 mM KCl, 2.5 mM CaCl2, 1.2 mM MgSO4, 5.6 mM glu-
cose, 1.2 mM KH2PO4, and 24.8 mM NaHCO3, pH 7.4), 
bubbled with 95% O2 and 5% CO2 at the constant tempera-
ture of 22°C, and attached to a force transducer (FT-03; As-
troNova). On both sides of the perfusion bath, at a distance 
of ∼2 mm from the preparations, plate platinum electrodes 
connected with a Grass stimulator allowed field electrical 
stimulation (S48 stimulator; AstroNova). The preparations 
were stretched to Lo (the length at which the maximal twitch 
force is observed), and their response to electrical stimulation 
was tested. If a response could be elicited, the preparation was 
stimulated for ∼30 min with supramaximal, low-frequency 
(0.03 Hz) stimuli. Tetanic isometric contractions were evoked 
(110 Hz, 500 ms, supramaximal amplitude) at Lo. Normalized 
tetanic force was expressed as maximal tetanic force/muscle 
volume (gr/µl). The output of the tension transducer was 
stored in a personal computer after analogue-to-digital con-
version and was recalled for analysis. A 1401 A/D converter 
(Cambridge Electronic Design) and CEA Spike2 software 
(Cambridge Electronic Design) were used.
Quantitative Pcr
Total RNA was isolated from triceps by using the TRIzol 
reagent (15596–026; Ambion) according to manufacturer’s 
instructions. Extracted RNA was quantified with NanoDrop 
(ND-1000 Spectrophotometer; EuroClone). cDNA was ob-
tained by retrotranscription with Oligo(dT) primers (Invit-
rogen) and SuperScript II Reverse transcription (Invitrogen). 
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Quantitative real-time PCR was performed in duplicates by 
using SYBR Green I master mix and LightCycler480 (Roche 
Molecular Diagnostics). ΔCt were calculated by using RSP29 
as normalizer. The following primers were used (Tm 60°C): 
angiopoietin-1: 5′-GAC AGT AAT ACA ACA CCG GGA 
AGA-3′ (forward), 5′-CAA AAC CCA TTT TAT ACT CCT 
TCCA-3′ (reverse); CD31: 5′-AGG GGA CCA GCT GCA 
CAT TAGG-3′ (forward), 5′-AGG CCG CTT CTC TTG 
ACC ACTT-3′ (reverse); IGF-1: 5′-GAA TGT TCC CCC 
AGC TGT TTC-3′ (forward), 5′-CAT TGC GCA GGC TCT 
ATC TG-3′ (reverse); MyoD: 5′-ACG GCT CTC TCT GCT 
CCT TT-3′ (forward), 5′-GTA GGG AAG TGT GCG TGCT-
3′ (reverse); Myogenin: 5′-GAC ATC CCC CTA TTT CTA 
CCA-3′ (forward), 5′-GTC CCC AGT CCC TTT TCT TC-3′ 
(reverse); Pax7: 5′-GAC TCG GCT TCC TCC ATC TC-3′ 
(forward), 5′-AGT AGG CTT GTC CCG TTT CC-3′ (re-
verse); and RSP29: 5′-AGT CAC CCA CGG AAG TTCG-3′ 
(forward), 5′-AGC ATG ATC GGT TCC ACT TG-3′ (reverse).
Quantification of leukocytes
Muscles were dissociated in RPMI 1640 containing 0.2% col-
lagenase B (Roche Diagnostics) at 37°C for 1 h. CD45-pos-
itive cells were purified by magnetic cell sorting by using 
anti-CD45 beads (Miltenyi Biotec) according to the manu-
facturer’s instructions and quantified by Countess (Invitrogen).
Blood samples from WT and Hmgb1+/− mice were 
collected from the tail vein, and circulating leukocytes were 
measured by Sysmex Kx21N according to the manufacturer’s 
instructions (Sismex Inc.). Leukocyte isolation from the liver 
was performed as previously described (Sitia et al., 2007).
Myoblast isolation, differentiation, and migration assays
15-d-old CD1 mice were sacrificed and muscles were cut 
in fine pieces and digested twice in collagenase and dispase 
medium (Gibco by Life Technologies) at 37°C for 20 min 
under strong agitation in a water bath. Pellets were resus-
pended in DMEM 10% FBS and passed through 70-µm 
and 40-µm filters. After incubation with red blood cell lysis 
buffer (Z314; Promega), cells were preplated on one 150-
mm uncoated dish for 2 h. Myoblasts in suspension were 
centrifuged, resuspended in proliferation medium (IMDM; 
1% glutamine, 1% penicillin/streptomycin, 0.1% gentami-
cin, 20% FBS, and 3% chicken embryo extract), and plated 
in collagen-coated 150-mm dishes. The purity of cells was 
assessed by FACS analysis by using SMC/2.6-biotin (a 
gift from S.-i. Fukada, Graduate School of Pharmaceutical 
Sciences, Osaka University, Osaka, Japan) and Streptavi-
din-APC (405207; Biolegend) as previously described (Fu-
kada et al., 2004). For the differentiation assay, cells were 
plated after 4 d in culture on Matrigel-coated slides in 
12-well plates (105 cells/well) in differentiating medium 
(IMDM; 1% glutamine, 1% penicillin/streptomycin, 0.1% 
gentamicin, 2% horse serum, and 1% chicken embryo ex-
tract) with or without 40 nM WT fr-HMGB1 or 40 nM 
3S. After 48 h, cells were fixed with 4% paraformaldehyde 
in PBS and stained with DAPI and anti–myosin heavy 
chain (clone MF20; DHSB).
For migration assays, 8-µm transwell filters (Corning) 
were first coated with collagen. Myoblasts were isolated 
as described above in the previous paragraph, after 2  h of 
preplating the suspended myoblasts were counted, and 5 × 
104 cells were transferred onto the upper side of the trans-
well chamber in proliferation medium alone or with 150 
pM human growth factor or 40 nM HMGB1 (WT fully 
reduced form or 3S mutant). After 16 h the cells were fixed 
with 4% paraformaldehyde, and Pax7 immunostaining (Pax7; 
Developmental Studies Hybridoma Bank) was performed. 
Alternatively, Pax7-positive cells were isolated by cell sort-
ing from Pax7-ZsGreen mice and tested with 40 nM fr-
HMGB1, 40 nM 3S, or 30 nM CXCL12 with or without 
10 nM anti-CXCL12 or 250 nM BoxA. Pax7-positive cells 
were counted in 10 random fields on the lower face of the 
transwell membrane at 10× magnification.
Single myofibers were prepared from the extensor dig-
itorum longus and TA muscles of 6-to 12-wk-old mice as 
previously described (Pasut et al., 2013). Individual myofi-
bers were plated on 35-mm dishes in proliferating medium 
(20% FBS and 3% chicken embryo extract in DMEM) in 
the presence or not of 40 nM fr-HMGB1 or 3S for 16 and 
72 h. Fibers were fixed with 4% PFA and stained with DAPI, 
anti-Pax7 mAb (Hybridoma Bank), anti–MyoD mAb (Dako-
Cytomation), and anti–Myogenin mAb (Hybridoma Bank). 
10 fibers/condition were counted in biological triplicate (n 
= 3 mice, 30 fibers in total per condition).
Bone marrow–derived macrophage polarization
Macrophages were obtained from bone marrow precur-
sor cells. In brief, bone marrow was obtained from mice 
by flushing the femur and tibia with DMEM. Cells were 
cultured for 7 d in DMEM conditioned by L929 cells 
(enriched in CSF-1). Macrophages were polarized toward 
a proinflammatory phenotype with 50 ng/ml IFN-γ in 
DMEM containing 10% FBS and were incubated with 
or without 40 nM fr-HMGB1 or 3S for 3 d. Macro-
phages were labeled with primary antibodies against iNOS 
(ab3523; Abcam), TNFα (ab34839; Abcam), CD163 (sc-
33560; Santa Cruz), TGFβ1 (ab64715, Abcam), and Cy3- or 
FITC-conjugated secondary antibodies (Jackson Immu-
noResearch Laboratories).
SPr
The analysis of the binding of HMGB1 forms to the MD-2 
or soluble RAGE (sRAGE) was conducted by using a Biacore 
T200 instrument (GE Healthcare Bio-Sciences). Binding re-
actions were done in HBS-EP buffer (Biacore) containing 
10 mM Hepes, 150 mM NaCl, 3 mM EDTA, pH 7.4, and 
0.05% polyoxyethylenesorbitan. MD-2 or sRAGE proteins 
were coated on the surface of CM5 dextran sensor chips 
by direct immobilization. MD-2 or sRAGE proteins were 
diluted to a concentration of 15 µg/ml in 10  mM acetate 
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buffer (pH 5.5 and pH 5.0, respectively). A 1:1 mixture of N- 
hydroxysuccinimide and N-ethyl-N-(dimethylaminopropyl) 
carbodiimide was used to activate 2 flow-cells of the CM5 
chip. One flow-cell was used as a reference and thus imme-
diately blocked on activation by 1 M ethanolamine (pH 8.5). 
The sample flow-cell was injected with the diluted MD-2 
or sRAGE at a flow rate of 10  µl/min. MD-2 or sRAGE 
injections were stopped when the SPR reached ∼1,200 or 
200 resonance units (RU). For binding assays, the analytes 
(fr-HMGB1, ds-HMGB1, or 3S) were diluted to 1  µM in 
HBS-EP buffer (filtered, 0.22 µm) and injected over the chips 
at a flow rate of 30 µl/min for 60 s at 25°C; the dissociation 
time was set to 1 min. Binding experiments were performed 
at least 3 times. Equilibrium dissociation constants (KD) were 
obtained by using the BIA Evaluation 2.0 software (GE 
Healthcare) and assuming a 1:1 binding ratio.
For CXCR4 binding assays, lentiviral particles were 
produced, characterized, and titrated as previously de-
scribed (Vega et al., 2011) by JetPei cotransfection of 
HEK293T cells with the LVT HM/GFP, PAX2, and VSVG 
plasmids (Tronolab) at a 1:1:1 ratio and plasmids for 
CXCR4 or siRNA for CXCR4 when needed. Lentiviral 
particles with a similar titration index were aliquoted and 
stored at −80°C. To activate carboxymethylated dextran, 
equal volumes of 0.1 M N-hydroxysuccinimide and 0.4 M 
1-ethyl-3-(3-dimethylamino-propyl) carbodiimide were 
mixed and injected (5 µl/min, 7 min, RT) over the sur-
face of a CM5 sensor chip (GE Healthcare). Hepes-buff-
ered saline (HBS-P: 10 mM Hepes, pH 7.4, 0.15 M NaCl, 
0.005% polyoxyethylenesorbitan) was used as an immobili-
zation running buffer. Lentiviral particles (107/ml) diluted 
in 10 mM sodium acetate buffer (pH 4.0) were injected 
over the activated surfaces (5 µl/min, 7 min, RT), followed 
by 1 M ethanolamine (pH 8.5, 5 µl/min, 7 min, RT) to 
deactivate remaining active carboxyl groups. We usually 
detected 6,000 RU of coupled lentiviral particles. All de-
terminations were performed by using a Biacore 3000 (GE 
Healthcare). Fr-HMGB1, 3S, and BoxA (1.25–40 nM) di-
luted in PBS-P buffer (137 mM NaCl, 10 mM Na2HPO4, 
1.76 mM KH2PO4, 2.7 mM KCl, and 0.005% polyoxyeth-
ylenesorbitan, pH 7.4) were injected over the immobilized 
viral particles (30 µl/min, 2 min, 25°C; association phase), 
followed by a 2-min injection period of PBS-P buffer 
alone over the surface (dissociation phase). Sensorgrams 
were corrected for signals obtained in two reference flow 
channels, a control chamber without viral particles, and 
another with viral particles obtained from HEK293 cells 
transfected with siRNA for CXCR4 that were activated 
and deactivated in parallel. All kinetic assays were followed 
by injection of 5 mM HCl to dissociate remaining ligand 
from the virions (regeneration phase). All steps were per-
formed by using the system’s automated robotics; all phases 
were followed in real time as a change in signal expressed 
in RU. Curves derived from these assays were used to gen-
erate kinetic constants, which were analyzed by fitting to a 
simple one-site interaction model with BIA Evaluation 4.1 
software (GE Healthcare).
Statistical analysis
Every experiment was replicated at least twice and was per-
formed at least in biological triplicate. Animals were assigned 
randomly to experimental groups (save for the matching 
between males and females), and no animals were excluded 
from the study. According to the 3R rules, a power calcu-
lation analysis was previously performed. The evaluator was 
blinded to the identity of the specific sample as far as the 
nature of the experiment allowed it. Bars represent the mean 
± SEM. Statistical significance was assessed by using the tests 
indicated in the figure legends (Prism 5; GraphPad Software). 
In brief, t tests and Mann-Whitney tests were used for pair-
wise comparisons, and ANO VA and Kruskal-Wallis tests were 
used for multiple comparisons. P-values <0.05 were consid-
ered statistically significant.
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